Inhibiting Beta-adrenergic and COX-2 Signaling During the Perioperative Period to Reduce Ovarian Cancer Progression

This study investigates the impact of perioperative inhibition of beta-adrenergic and COX-2 signaling in ovarian cancer patients undergoing debulking surgery. The trial aims to assess the feasibility, safety, and biological effects of a combination of propranolol and etodolac in reducing cancer metastasis and improving immune responses.

Trial Details

NCT ID
NCT06839144
Phase
PHASE2
Sponsor
Tel-Aviv Sourasky Medical Center
Status
RECRUITING
Cancer Type
Ovarian Cancer
Interventions
  • Propranolol (Beta-Blocker) and Etodolac (COX-2 Inhibitor)
  • Placebo (Matching for Propranolol & Etodolac)
Locations (sample)
  • Ramat Gan, Israel|32.08227,34.81065
  • Tel Aviv, Israel|32.08088,34.78057

Key Eligibility Criteria

  • ASA score 1-3 or ECOG Performance Status of 0 to 2
  • Patients with a suspected high-grade ovarian epithelial cancer based on imaging, clinical examination, CA125, and/or tumor biopsy
  • Patients planned for surgery for primary surgery, or interval debulking surgery for ovarian cancer
  • Signed informed consent form

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Ovarian Cancer Trials on Trialify →